Drug intelligence / Profile preview

Promescent

Development stage
Phase 3
Lead developer
Absorption Pharmaceuticals
Modality
Small Molecules
Administration
Topical
01

Overview

Promescent is a topical desensitizing spray containing lidocaine, specifically formulated for the treatment of premature ejaculation. It functions as a local anesthetic that reduces sensitivity in the penis by numbing the sensory nerves, thereby delaying ejaculation. Originally developed by Dr. Ron Gilbert, the product is marketed as an over-the-counter (OTC) drug under the FDA monograph for male genital desensitizing products. A Phase 3 clinical trial (NCT02241460) was conducted by Dr. Eugene Y. Rhee to evaluate its efficacy and safety compared to placebo.

Brand names
Promescent
Other names
Promescent Lidocaine Spray
02

Targets

GABRR (GABA-A receptor subunit rho)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)TRPV1 (Transient receptor potential cation channel subfamily V member 1)SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN5A (Sodium channel protein type 5 subunit alpha)SCN9A (Sodium channel protein type 9 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on Promescent.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Promescent.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call